Tags : V920 (rVSV∆G-ZEBOV-GP)

Merck Reports Initiation of BLA Filling for V920 (rVSV∆G-ZEBOV-GP) Under

Shots: The BLA filling is in response to the Breakthrough Therapy designation granted in 2016 to V920, taken alone or in combination to treat serious or life-threatening disease or condition In 2014, Merck gained rights for V920 from NewLink Genetics Corporation which was initially developed by Public Health Agency of Canada’s National Microbiology Laboratory V920 […]Read More